By Michael Dabaie
BriaCell Therapeutics Corp. shares more than doubled in Wednesday trading, recently up 111% to $6.70 after the company reported a 12 months overall survival benefit in advanced breast cancer patients.
Share volume topped 126 million, versus the 65-day average volume of 971,221.
The clinical-stage biotechnology company updated on the overall survival data on previously disclosed advanced breast cancer patients. The company said the women were treated with BriaCell's lead candidate Bria-IMT as monotherapy and also in combination with drugs including Keytruda and retifanlimab.
BriaCell reported 21.4 months survival for the top responder, plus 100% resolution of an orbital tumor that metastasized behind the patient's left eye.
Write to Michael Dabaie at michael.dabaie@wsj.com
"breast" - Google News
June 03, 2021 at 12:50AM
https://ift.tt/2SRBtSK
BriaCell Shares More Than Double After Breast Cancer Data - MarketWatch
"breast" - Google News
https://ift.tt/2ImtPYC
https://ift.tt/2Wle22m
Bagikan Berita Ini
0 Response to "BriaCell Shares More Than Double After Breast Cancer Data - MarketWatch"
Post a Comment